The Oxtend TM-01 study: Debio 4126, ​a new 12-week octreotide formulation, provides maintenance of disease control in patients with acromegaly switching from long-acting somatostatin analogues (SSAs)

Presented at the 19th Pituitary congress 2025

Annick Menetrey¹, Dalit Rechavi-Robinson¹, Yanina Negievich¹, Justyna Nowakowska¹, Daniel Biasse¹, Moritz Marquardt¹, Bruno Gavillet¹, Anne Bellon¹,
Pedro Caetano¹, Przemysław Witek², Mikkel Andreassen³, Philippe Chanson⁴, Thierry Brue⁵

1 Debiopharm International SA, Lausanne, Switzerland
2 Medical University of Warsaw, Department of Internal Medicine Endocrinology and Diabetes, Warsaw, Poland
3 Rigshospitalet, Department of Nephrology and Endocrinology, Copenhagen, Denmark
4 Assistance Publique-Hôpitaux de Paris, Université Paris-Saclay, Hôpital Bicêtre, Service d’Endocrinologie et des Maladies de la Reproduction et Centre de Référence des Maladies Rares de l’Hypophyse (HYPO), Le Kremlin-Bicêtre, France
5 Aix Marseille Univ, INSERM, UMR1251, Marseille Medical Genetics, Institut MarMaRa and Department of Endocrinology, La Conception Hospital, APHM, Marseille, France

Introduction

Debiopharm  is developing Debio 4126, a 12‑week octreotide formulation, for the treatment of patients with acromegaly. Final results from the acromegaly cohort in the OxtendTM-01 (NCT05364944, also known as Debio 4126-102) are presented here for the first time.